Big announcement

1. Oriental Selection: New Oriental and Yu Minhong have promised to purchase a total of HK$700 million of company shares

$NEW ORIENTAL-S (09901.HK)$and Yu Minhong have each promised to purchase a total value of HK$700 million on the Stock Exchange at market prices$EAST BUY (01797.HK)$Shares, of which: (a) New Oriental has promised to purchase Oriental Select Shares with a total value of HK$660 million, which will be held by New Oriental Benefit after purchase (i.e. New Oriental Commitment); and (b) Yu Minhong has promised to purchase Oriental Selected Shares with a total value of HK$40 million, which will be held by Yu Minhong or a corporation controlled by him after purchase (i.e., a directors' commitment). The share purchase will be carried out gradually over a period of 6 to 12 months from the date of this announcement, and will be subject to and compliance with applicable laws and regulations, including listing rules and securities and futures regulations.

2. Yao Ming and Yingxi: Adjusted net profit is expected to increase by more than 100% in 2023

$WUXI XDC (02268.HK)$An announcement was issued. According to the preliminary assessment of the Group's unaudited comprehensive management accounts for the year ended 31 December 2023 prepared in accordance with IFRS, the Group is expected to record (i) an increase of more than 100% in sales revenue; (ii) an increase of more than 80% in net profit; and (iii) an increase of more than 100% in adjusted net profit over the same period of the previous year.

3. Saisheng Pharmaceutical: Vaborem® completed phase III clinical trial in China and enrolled all subjects

$SCICLONE PHARMA (06600.HK)$An announcement was made that the phase III clinical trial of the novel antimicrobial drug Vaborem® (meropenem and vibobactan for injection) (“Vaborem®”) in China has successfully completed the enrollment of all subjects. The study aimed to evaluate the efficacy and safety of Vaborem® in patients with complicated urinary tract infections (“CUTi”) (including acute pyelonephritis).

4. Xianruida Healthcare: PERIDGE® registration application approved by China National Drug Administration

$ACOTEC-B (06669.HK)$An announcement was issued. On January 30, 2024, the company received approval from the China National Drug Administration to register Peridge®, a peripheral incised balloon dilation catheter. This product is suitable for the treatment of occlusive lesions of autologous or synthetic arteriovenous fistula tubes used for hemodialysis.

Earnings Report

$SHINSUN HOLD GP (02599.HK)$Total revenue in 2022 was about 19.701 billion yuan, a year-on-year decrease of about 54.9%

$CMRU (01636.HK)$Losses attributable to owners in 2022 of $4.763 billion

$SINOFERT (00297.HK)$: Expected net profit of 550 million to 650 million yuan in 2023

$BII TRANS TECH (01522.HK)$It is expected that in 2023 RMB caliber revenue and profit for the year will not be lower than the same period last year

$LEFTFIELD PRINT (01540.HK)$Yingxi: Net profit is expected to increase 180% to 220% year-on-year in 2023

Pharmaceutical Innovation

$SSY GROUP (02005.HK)$: Isoprenaline hydrochloride was approved by the State Drug Administration and registered as an active ingredient for use in marketed formulations

$ACOTEC-B (06669.HK)$: PERIDGE registration application approved by the State Drug Administration

Acquisition and sale

$PAK TAK INT'L (02668.HK)$Proposed acquisition of all shares in a company that produces and sells metal products

$FIRST SERVICE (02107.HK)$: Proposed acquisition of 51% of Dalian World Airlines Construction Project

Equity incentives

$HG SEMI (06908.HK)$A total of 7.54 million bonus shares were granted

$XPENG-W (09868.HK)$A total of 1.29 million restricted share units were granted to 208 employees

Increase or decrease holdings

$CH ENERGY ENG (03996.HK)$: Controlling shareholder$China Energy Engineering Corporation (601868.SH)$The Group increased its total A-share holdings by 14.0841 million

$DONGFANG ELEC (01072.HK)$: Dongfang Electric Group increased its A-share holdings by 7.11 million

Repurchase cancellation

$ASYMCHEM (06821.HK)$It is proposed to repurchase A-shares for 600 million yuan to 1.2 billion yuan

$AIA (01299.HK)$On January 31, it cost HK$183 million to buy back 3 million shares

$HSBC HOLDINGS (00005.HK)$On January 30, HK$122 million was spent to buy back 2 million shares

$DFZQ (03958.HK)$Repurchase a total of 34.84 million A shares of the company

$HAITONG SEC (06837.HK)$On January 31, it spent 87.475 million yuan to buy back 10 million A-shares

$XIAOMI-W (01810.HK)$On January 31, it cost HK$49.48 million to buy back 4 million shares

$KUAISHOU-W (01024.HK)$On January 31, it cost HK$39.93 million to repurchase 1,012,000 shares

$BEKE-W (02423.HK)$On January 30, it cost 5 million US dollars to buy back 1.06 million shares

$HAIER SMARTHOME (06690.HK)$On January 31, it spent 26.91 million yuan to buy back 1.2 million A-shares

$KINGDEE INT'L (00268.HK)$On January 31, 3.3 million shares were repurchased at HK$254.964 million

$HISENSE HA (00921.HK)$On January 31, it spent 208.565 million yuan to buy back 8352,000 A-shares

$KINGSOFT (03888.HK)$On January 31, it cost HK$20 million to buy back 1.054 million shares

$ESR (01821.HK)$On January 31, it cost HK$16.991,700 to repurchase 1.7 million shares

$COSCO SHIP HOLD (01919.HK)$On January 31, it cost HK$148.52 million to repurchase 1.8 million shares

$MNSO (09896.HK)$On January 31, 430,000 shares were purchased at HK$13.98 million

$HAOHAI BIOTEC (06826.HK)$On January 31, it spent 113.14 million yuan to buy back 128,800 A-shares

$SWIRE PACIFIC A (00019.HK)$178,000 shares were repurchased at HK$10.8 million on January 31

edit/ruby